Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 28Gastrointestinal Stromal Tumors 4Colonic Neoplasms 4Carcinoma, Hepatocellular 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Neoplasm Metastasis 3Rectal Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sarcoma 1Rhabdomyosarcoma 1Renal Insufficiency 1Physician Education 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Noonan Syndrome 6 1Metastatic Pancreatic Adenocarcinoma 1Melanoma 1Liver Neoplasms 1Liposarcoma 1Insulinoma 1

Interventions

regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bile Duct Diseases × regorafenib × Clear all
NCT02115542 2021-10-12

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
39 enrolled 11 charts
Gastrointestinal

Bile Duct Diseases, Bile Duct Neoplasms, Carcinoma, Gallbladder Diseases, Gallbladder Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡